PER200

About Perseo Pharma

Perseo Pharma is a Swiss biotech developing next-generation enzyme replacement therapies using its proprietary nano-shield platform. The company's technology encapsulates enzymes in silica-based nanoparticles with muco-adhesive coatings, enhancing intestinal residence time and activity while remaining non-systemic. Its pipeline targets digestive enzyme deficiencies like EPI and rare metabolic disorders, with a strategic R&D collaboration with Nestlé Health Science providing validation and resources. Founded in 2019, the company is privately held and currently in the preclinical stage.

Therapeutic Areas